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ABSTRACT
Acute pancreatitis is a common digestive
disease of which the severity may vary
from a mild, edematous to a severe,
necrotizing disease. An improved out-
come in the severe form of the disease is
based on early identification of the dis-
ease severity. The pathogenesis of acute
pancreatitis is still only partially under-
stood. However, the premature activa-
tion of trypsinogen to trypsin in the aci-
nar cell in the pancreas is considered a
possible key event in the development of
acute pancreatitis. The pivotal role of
trypsinogen activation makes trypsin-
based laboratory markers potentially
useful as markers reflecting the severity
of acute pancreatitis.
The main purpose of the present
clinical study was to evaluate the value of
new prognostic markers (trypsinogen
activation peptide, trypsinogen-2 and
the urinary trypsinogen-2 dipstick test)
in the severity assessment of acute pan-
creatitis as well as to gain insight into the
pathogenesis of acute pancreatitis.
The study population consisted of
219 patients with mild acute pancreatitis,
57 patients with severe acute pancreati-
tis, 50 patients with endoscopic retro-
grade cholangiopancreatography-induced
acute pancreatits, 61 controls (patients
without endoscopic retrograde cholangi-
opancreatography-induced acute pan-
creatitis) and 32 patients with abdominal
pain similar to that of acute pancreatitis.
The study shows that the measure-
ment of urinary trypsinogen activation
peptide as well as of trypsinogen-2 are
useful in the prediction of a severe out-
come in patients in the early phase of the
disease. Also, patients with organ failure
that resolves within 48 hours are unlikely
to develop complications later in the
course of the disease. The novel rapid
urinary trypsinogen-2 test strip rapidly
identifies patients needing further evalu-
ation and therapeutic measures in the
early phase of acute pancreatitis. The re-
sults further suggest that in the early
phase of acute pancreatitis, trypsinogen-
1 seems to play a central role in the
pathogenesis of acute pancreatitis. How-
ever, trypsinogen-2 may play a more sig-
nificant role in the later phase of the dis-
ease than earlier believed.
In conclusion, the timely recognition
of those patients who develop severe
acute pancreatitis is still a challenge. At
present, no single biochemical marker is
ideal for this purpose. The best results
will be achieved by using a combination
of different tests. Future studies on vari-
ous combinations are needed to show
which combination will be most useful
in predicting the severity of acute pan-
creatitis.
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91 INTRODUCTION
Acute pancreatitis (AP) is a common di-
gestive disease and the most frequent
disorder of the pancreas. It is an inflam-
matory process of the pancreas, with var-
iable involvement of other regional tis-
sues or remote organ systems (Bradley
1993). As early as 1896, autodigestion of
the pancreas by premature activation of
pancreatic proteases was suggested as an
essential event in the pathogenesis of
acute pancreatitis (Chiari 1896), result-
ing in a disease ranging from mild pan-
creatic intestinal edema to large conflu-
ent necrosis of pancreatic and
peripancreatic tissue. Considerable inter-
est has focused on the mechanisms by
which those enzymes might become ac-
tivated, prematurely, causing pancreatic
injury. The premature activation of
trypsinogen to trypsin in the acinar cell
in the pancreas is considered a possible
key event in the development of acinar
cell injury (Steer 1998), leading to auto-
digestion.
In most cases, AP is a mild self-limit-
ing disease that resolves spontaneously
without complications, but the severe
necrotizing form of the disease, which
occurs in about 20% of attacks, is a life-
threatening condition with high morbid-
ity. Mortality may reach 40%, especially
if bacterial contamination of the pancre-
atic necrosis occurs (Beger et al. 1986).
An improved outcome in the severe
form of AP is based on early identifica-
tion of disease severity and subsequent
focused management of these high-risk
patients.
Our knowledge of the pathogenesis
of AP is still fragmentary and no specific
treatment exists. The prognostic meth-
ods available to identify the severe cases
are generally considered unsatisfactory
or too cumbersome. Diagnosis of this fa-
tal disease may be obtained only at au-
topsy in as many as 42% of the cases
(Wilson et al. 1988). Rapid severity as-
sessment remains a challenge, and an ob-
vious clinical need exists for a simple test
that can identify patients at risk of devel-
oping a severe attack of AP.
The aims of this study were to evalu-
ate the value of new prognostic markers
of severity and to gain insight into the
obscure pathogenesis of human acute
pancreatitis.
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2 REVIEW OF THE
LITERATURE
2.1 Historical background
While the ancient Egyptians and Babylo-
nians developed medicine to an aston-
ishing degree and were knowledgeable
about many anatomical structures, they
failed to identify the pancreas. It was the
Greek anatomist and surgeon Hero-
philus, born in about 335 B.C. in Chal-
cedon, who apparently first described the
pancreas, but did not name it. Not until
400 years later, in the late first and early
second century A.D., did Ruphos of
Ephesus name the organ “pancreas”. In
Greek, the word πανκρεας means “all
flesh” (from παν [“pan”] = all, and
κρεας [“kreas”] = flesh). The pancreas
remained, however, a hidden organ
throughout the Middle Ages, and was
still considered only a pad – a cushion
behind the stomach to protect the major
vessels – at the time when William Har-
vey described circulation. Apparently Dr
Nicholas Tulp published the first clear
description of AP in 1652. After that few
physicians contributed related knowl-
edge until in the nineteenth century,
when physicians made many significant
discoveries. In 1867, Wilhelm Kühne
(Kühne 1867) isolated trypsin, and in
1875, Rudolph Heidenhain demonstrat-
ed that trypsin and other proteases were
stored within the pancreas as inactive
proenzymes (Heidenhain 1875). In 1889,
Reginald Fitz presented the first classifi-
cation system of AP (Fitz 1889), and the
pathogenesis of AP became a question of
significant interest in the latter half of
the nineteenth century. Hans Chiari sug-
gested the concept of autodigestion, in-
trapancreatic proenzyme activation, as
the cause of pancreatic necrosis in 1896
(Chiari 1896). In the beginning of the
twentieth century, the two most impor-
tant etiological factors of AP were firmly
established. In 1901 Eugene Opie de-
scribed the association between gall-
stones and AP (Opie 1901), and alcohol
was firmly established as an etiological
factor in 1917 (Symmers 1917). Comfort
and Steinberg reported hereditary AP in
1952, describing a family with AP in
three successive generations. The nine-
teenth century and the first twenty years
of the twentieth century saw an almost
complete absence of diagnostic tools of
AP. Most diagnoses were made at autop-
sy. In 1908 Julius Wohlgemuth published
a method for the determination of pan-
creatic amylase in serum (Wohlgemuth
1908), however, it was seldom used until
1929, when Robert Elman in the United
States demonstrated its significance and
popularized its utilization in the diagno-
sis of AP (Elman 1929). The determina-
tion of serum amylase activity is still the
principal laboratory method for the di-
agnosis of AP today. Once the diagnosis
of AP was established, the search began
for a marker to differentiate between the
necrotizing and edematous form of the
disease. Methemoglobinemia was uti-
lized in the 1960s (Northam 1963), α
1
-
antitrypsin (AAT) (Borgström and Las-
son 1984), α
2
-macroglobulin (Lasson
and Ohlsson 1984), and C-reactive pro-
tein (CRP) (Puolakkainen et al. 1987) in
the 1980s. In the 1990s, group II phos-
pholipase A
2
 (PLA2) (Grönroos and
Nevalainen 1992), trypsinogen activation
peptide (TAP) (Gudgeon et al. 1990),
and interleukin-6 (IL-6) (Heath et al.
1993) were evaluated as prognostic
markers, just to mention a few of the
more than 20 different markers reported
to have some prognostic value in differ-
entiating between the necrotizing and
edematous forms of AP (Larvin 1996;
Frossard et al. 2001). In 1974, John Ran-
son came up with the concept of com-
bining different parameters to identify
those patients at risk of developing a se-
vere form of the disease (Ranson et al.
1974). Two of the most important ad-
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vances that radically changed the imag-
ing of the pancreas was the introduction
of ultrasound in 1967 (Holmes 1967)
and the introduction of computed tom-
ography (CT) in the mid-1970s (Haaga
et al. 1976). Endoscopic retrograde
cholangiopancreatography (ERCP) was
introduced in the late 1960s (McCune et
al. 1968) and belongs currently to the ar-
mament for the treatment of biliary AP.
The rationale of surgery in AP has
evolved during the last 100 years from
exploratory laparotomy in the late nine-
teenth and early twentieth centuries, to
total pancreatectomy in severe AP in the
late 1960s and 1970s, to the present con-
cept that patients with severe necrotizing
disease, complicated with infected pan-
creatic necrosis, benefit from delayed
necrosectomy and drainage (Uhl et al.
2002b).
2.2 Epidemiology of acute
pancreatitis
AP is a common disorder observed in
every part of the world (Steinberg and
Tenner 1994). The true incidence of AP
remains controversial, and geographical,
etiological, and diagnostic variations
hinder accurate assessments. Studies
have shown that in 12% to 42% of pa-
tients who die of AP, diagnosis occures
only at autopsy (Wilson et al. 1988; Ap-
pelros and Borgström 1999). The inci-
dence rates of AP vary considerably in
different countries. Relatively low figures
are observed in England 12/100,000
(Giggs et al. 1988) and the Netherlands
16/100,000 (Eland et al. 2000), whereas
medium-high figures are seen in Scot-
land 42/100,000 (McKay et al. 1999) and
Sweden 38/100,000 (Appelros and Borg-
ström 1999), and high figures are ob-
served in the United States of America
79.8/100,000 (Go 1994) and Finland 73/
100,000 (Jaakkola and Nordback 1993).
The incidence of AP seems to increase in
industrialized countries (Lankisch et al.
1989; Wilson and Imrie 1990; Jaakkola
and Nordback 1993; McKay et al. 1999;
Eland et al. 2000). In Finland, where al-
cohol is the main cause of AP, the in-
creased incidence of AP was significantly
correlated with the general increase in
alcohol consumption between 1970 and
1989 (Jaakkola and Nordback 1993).
Data on increased incidence should,
however, be cautiously interpreted since
the diagnostic criteria and methodology
in the different studies vary widely.
Therefore, better diagnostic procedures
may also explain an increased incidence.
2.3 Etiology of acute
pancreatitis
It is important to clarify the underlying
cause of an attack of AP because the eti-
ology will affect decision-making and
further therapeutic procedures targeted
at preventing the development of chron-
ic pancreatitis. Worldwide, gallstones are
the most common cause of AP, account-
ing for approximately 45% of cases, alco-
hol being the second most common, ac-
counting for 35% of cases (Steinberg and
Tenner 1994). The proportion of the two
main causes depends on geographic and
cultural factors. In southern Europe,
gallstones are the predominant cause of
AP (Greece, Italy and Spain), whereas
central and northern Europe (Hungary,
Switzerland and Germany) see a similar
frequency of the two factors, or a pre-
dominance of alcohol (Fernandez-Cruz
et al. 1994; Gloor et al. 2001; Gullo et al.
2002). In studies from the United King-
dom and Asia, gallstone-induced AP pre-
dominates (Leese et al. 1988; Fan et al.
1993), whereas in the United States of
America and Finland, alcohol is the main
cause (Agarwal and Pitchumoni 1986;
Jaakkola and Nordback 1993). In Fin-
land, alcohol is to blame for about 60%
to 70% of the cases of AP, and gallstones
for only about 15% to 20% (Puolakkain-
en et al. 1987; Jaakkola and Nordback
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1993). There is a predominance of men in
those studies where alcohol is the main
etiology of AP, and the mean age tends to
be low in this group of patients (Steinberg
and Tenner 1994; Uhl et al. 1996; Gullo et
al. 2002). Other rarer causes of AP in-
clude various drugs, trauma (accidental
or iatrogenic), ERCP, metabolic abnor-
malities (hypertriglyceridemia, hypercal-
cemia), obstruction (tumors, pancreas di-
visum, choledochocele), infection (viral,
parasitic, bacterial), and vascular abnor-
malities (emboli, ischemia, vasculitis)
(Steinberg and Tenner 1994). Recently, re-
searchers have described hereditary forms
of AP caused by a mutation in the
trypsinogen-1 gene allowing premature
activation of trypsinogen to trypsin
(Whitcomb et al. 1996). Finally, about
10% of the cases of AP are called idio-
pathic with no identifiable etiology
(Steinberg and Tenner 1994).
2.4 Pathogenesis of acute
pancreatitis
2.4.1 General
Our knowledge of the pathogenesis of
AP is limited and is primarily based on
experimental models because clinical
studies of the early stages of AP in hu-
mans are impossible. No experimental
model simulates the human situation
entirely, but such models are useful to
investigate the pathogenesis and diag-
nostic approaches in AP (Schmid et al.
1999a). The intracellular events are still
uncertain, but many believe that the ear-
liest changes in the disease occur within
the acinar cells, leading to trypsin activa-
tion (Steer 1998), triggered by events
that are largely extrapancreatic in origin.
Active trypsin has the ability to activate
all the other pancreatic zymogens in a
cascade-like manner, resulting in de-
struction of pancreatic tissue. Once this
process has begun, the clinical pattern
and outcome of the disease is practically
independent of the cause of the attack.
As mentioned earlier, the two most clini-
cally important extrapancreatic-trigger-
ing events are the passage of either bil-
iary tract stones or the ingestion of
alcohol, accounting for 80% of cases
(Steinberg and Tenner 1994). The risk of
AP in patients with gallstones, however,
is low; only 3.4% of these will develop
AP (Moreau et al. 1988), although this
may increase to as much as 20% to 30%
in those with microlithiasis (Farinon et
al. 1987). There also seems to be an indi-
vidually variable organ sensibility to al-
cohol toxicity, since among alcoholics
the incidence of liver cirrhosis is 15%,
pancreatitis occures in 5%, and the com-
bination of these two occurs in only 1%
(Dreiling and Koller 1985).
2.4.2 Gallstone-induced disease
The association between gallstones and
AP was recognized roughly a decade ago
(Opie 1901). In 1974, Acosta and Ledes-
man demonstrated that the passage of
biliary tract stones into or through the
terminal biliopancreatic duct system
triggers AP (Acosta and Ledesma 1974).
They recovered gallstones in the feces of
more than 90% of patients with gall-
stone-related AP, whereas less than 15%
of patients with gallstones but no evi-
dence of AP had gallstones in their feces.
The mechanism by which gallstones
might trigger AP remains the subject of
some debate. The theory known as the
“common channel” theory suggests that an
impacted stone in the terminal bile duct
might create behind it a common channel
allowing bile to reflux into the pancreatic
duct and trigger AP (Opie 1901). In many
patients, however, the union of the main
bile duct and main pancreatic duct is too
short to allow the formation of such a
common channel (Elliot 1957).
According to what is called the “duo-
denal reflux” theory, stones may pass
through the sphincter of Oddi and
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stretch the muscle, making it incompe-
tent (McCutcheon 1964). As a result, du-
odenal juice containing activated pancre-
atic digestive enzymes could reflux
through the incompetent sphincter into
the pancreatic duct, causing AP. This
theory is unlikely in human biliary AP,
however, because patients can undergo
division of the sphincter during sphinc-
terotomy without marked risk for AP.
The most widely accepted theory is
based on the concept of pancreatic duct
obstruction. This theory suggests that
impaction of the triggering gallstone or,
alternatively, edema and inflammation
resulting from the passage of such a
stone could obstruct the pancreatic duct.
Continuing secretion into the obstructed
duct causes ductal hypertension, result-
ing in extravasation of pancreatic juice in
the parenchyma, triggering pancreatic
injury (Lerch et al. 1993).
2.4.3 Alcohol-induced disease
The effect of alcohol ingestion seems to
result in a series of changes in acinar and
ductal cell function, ductal pressure, and
tone of the sphincter of Oddi. The duo-
denopancreatic reflux theory suggests
that alcohol reduces the tone of the
sphincter of Oddi, allowing reflux of ac-
tivated enzymes into the pancreatic duct
(Johnson and Doppman 1967). This is,
however, unlikely in humans for reasons
already mentioned before.
The ductal hypertension/obstruction
theory is considered to be the most plau-
sible mechanism in biliary AP (Lerch et
al. 1993). In alcohol-induced AP, ethanol
leads to an increase of muscular tone of
the sphincter of Oddi (Sarles 1973; Har-
vey et al. 1988) and, in addition, induces
pancreatic hypersecretion, causing duct-
al hypertension (Robles Diaz et al. 1985).
The cholinergic theory on alcohol-
induced AP is based on the idea that
chronic alcohol intake results in a
dysregulation of pancreatic secretion
(Grönroos 1990). This mimics the situa-
tion of a hyperstimulated pancreas, a
mechanism known to induce AP (Grön-
roos 1990). Furthermore, increased duct
permeability is observed after alcohol in-
gestion (Harvey et al. 1988), altering the
susceptibility of the pancreas to damage.
Ethanol or its metabolites may also
directly injure the pancreas (Nordback et
al. 1991), and decreased blood circula-
tion in the gland has been observed after
alcohol ingestion, which may contribute
to the initiation of AP or worsen the
course of the disease by limiting the in-
flow of protective factors such as AAT
and α
2
-macroglobulin (Dib et al. 1993).
Although the clinical association of
AP with gallstones and alcohol ingestion
is well established, the underlying mech-
anistic explanation remains incomplete.
As one can realize from the variety of
theories presented, more than one mech-
anism may be responsible for the initia-
tion of AP.
2.4.4 Intracellular pathogenesis
Much research has focused on the un-
derstanding the early intercellular mech-
anisms that drive AP from the triggering
event to the manifest disease. It is now
widely accepted that protease activation
(notably trypsinogen) plays a key role in
these intracellular events (Steer 1998;
Whitcomb 1999a). The excess of oxygen-
derived free radicals and high intracellu-
lar calcium concentrations, however, also
appear to play an important role in the
intracellular events leading to acinar cell
injury (Klar and Werner 2000).
Under normal circumstances, many
digestive and lysosomal proteins are syn-
thesized in the rough endoplasmatic re-
ticulum and then transported to the
Golgi complex, where they are sorted
and separated: with secretory proteins
into zymogen granules, and lysosomal
hydrolases into lysosomes (Palade 1975).
The integrity of this compartmenation
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seems important for the safe transport of
the hazardous digestive enzymes (Glas-
brenner and Adler 1993). These are syn-
thesized and secreted as proenzymes into
the duodenum; in addition, the pancre-
atic secretory trypsin inhibitor (PSTI) is
secreted and transported together with
the proenzymes. PSTI is considered the
first line of defense against inappropriate
trypsinogen activation (Pubols et al.
1974; Rinderknecht 1986).
There are two major theories con-
cerning trypsinogen activation in AP: the
co-localization theory (Hofbauer et al.
1998; Otani et al. 1998; Steer 1998) and
the theory of trypsinogen autoactivita-
tion (Kassell and Kay 1973; Whitcomb
1999a, 1999b). According to the co-local-
ization theory, a blockade of secretion, as
a direct result of the etiological factor
(Glasbrenner and Adler 1993), results in
the co-localization of digestive enzyme
zymogens with lysosomal hydrolase
granules (Steer 1998). In experimental
models of AP, cathepsin B, when co-lo-
calized with trypsinogen was capable of
activating trypsinogen to active trypsin
(Greenbaum 1959). Researchers have
shown this to be an early as well as criti-
cal event in AP, resulting in acinar cell
injury (Saluja et al. 1997; Steer 1998).
Additionally, experimental studies have
shown that the inhibition of cathepsin B
can effectively prevent trypsinogen acti-
vation (Saluja et al. 1997; Van Acker et al.
2002) and, in addition, cathepsin B
knockout mice seem to be protected
against cerulein-induced AP (Halangk et
al. 2000). Co-localization seems, howev-
er, to occur in normal acinar cells as well,
and the extent of co-localization does
not correlate with the severity of AP
(Lüthen et al. 1995).
Trypsinogen has the ability to au-
toactivate to active trypsin under normal
conditions (Kassell and Kay 1973; Kukor
et al. 2003). The autoactivation theory
suggests that autoactivation becomes
pathological only when a secretory
blockade is present and one of the two
defense mechanisms that regulate the
process is overwhelmed (Whitcomb
1999b). PSTI inhibits trypsin and pre-
vents further autoactivation of trypsino-
gen and other proenzymes within the
pancreas, but during excessive trypsino-
gen activation, the PSTI inhibitory ca-
pacity is overwhelmed and trypsin activ-
ity continues to increase. The second line
of defense is represented by trypsin itself.
Once active, trypsin not only activates
trypsinogen, but can also degrade and
inactivate trypsin. This theory is sup-
ported by the detection of trypsinogen
mutations, resulting in inactivation-
resistant trypsin variants (Whitcomb
1999b), which leads to uncontrolled zy-
mogen activation and initiation of auto-
digestion of the gland, and then to pan-
creatitis.
2.4.5 Trypsinogens
2.4.5.1 General
The exocrine pancreas synthesizes and
secretes more protein per cell than does
any other exocrine organ. Trypsinogen is
the most important human digestive
proenzyme and the major proenzyme in
pancreatic juice, accounting for 19% of
the total protein. The human pancreas
secretes three trypsinogen isoenzymes:
the major trypsinogen isoenzymes
trypsinogen-1 (cationic trypsinogen)
and trypsinogen-2 (anionic trypsinogen)
(Figarella et al. 1975) and the third
minor isoenzyme mesotrypsinogen
(Scheele et al. 1981; Rinderknecht et al.
1984). The molecular weights (MW) of
the trypsinogens are about 25 000.
Trypsinogens are single-stranded mole-
cules containing eight disulfide bridges
encoded by three PRSS (protease, serine)
genes (PRSS1, PRSS2 and PRSS3) on
chromosome 7q32 (Emi et al. 1986; Tani
et al. 1990). An alternatively spliced form
of mesotrypsinogen is expressed in the
human brain (Wiegand et al. 1993).
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In the duodenum, trypsinogens are
converted into active trypsin-1, trypsin-2,
and mesotrypsin by the duodenal brush-
border enzyme enterokinase (Kassell and
Kay 1973). Trypsin, in turn, activates oth-
er trypsinogen molecules as well as pro-
carboxypeptidases A and B, chymot-
rypsinogen, proelastase, prophospholi-
pase A
2
, and procolipase (Marshall 1993).
Trypsinogen is also secreted by ovar-
ian cancer (Koivunen et al. 1989), vari-
ous tumor cell lines derived from gastric
carcinoma, colonic carcinoma (Miyata et
al. 1999), and pancreatic carcinoma
(Miszczuk-Jamska et al. 1991). More-
over, trypsinogen has been detected by
immunohistochemistry in several nor-
mal tissues such as skin, esophagus,
stomach, small intestine, lung, kidney,
liver, and bile duct (Terada et al. 1993;
Koshikawa et al. 1998), as well as tumors
including lung (Kawano et al. 1997),
ovarian (Hirahara et al. 1998), colonic,
and gastric cancer (Miyata et al. 1999).
2.4.5.2 Trypsinogen-1 and -2
Trypsinogen-1 and -2 display about 90%
sequence homology at the amino acid
level (Guy et al. 1978). Of total trypsino-
gen production, only 0.01% to 0.1% is
normally distributed to the extracellular
tissue space (Borgström and Ohlsson
1978). In healthy subjects, serum concen-
trations of trypsinogen-1 are higher than
those of trypsinogen-2 (Kimland et al.
1989), trypsinogen is eliminated from the
circulation, without being markedly acti-
vated, by glomerular filtration and varia-
ble tubular absorption and degradation in
the kidney (Borgström and Ohlsson
1978). Furthermore, trypsinogen-1 is ac-
tivated more readily and is more resistant
to autolysis than is trypsinogen-2 (Co-
lomb et al. 1979). In 1996, David Whit-
comb and colleages reported a mutation
in the trypsinogen-1 gene associated with
hereditary AP. The mutation is thought to
result in a trypsin resistant to inactivation,
which has led to the assumption that
trypsinogen-1 is more important than
trypsinogen-2 in the pathogenesis of AP
(Whitcomb 1999b). On the other hand,
in AP the concentrations of trypsinogen-
2 in serum and in urine are much higher
than those of trypsinogen-1 (Itkonen et
al. 1990; Hedström et al. 1996d). In ac-
cordance with these findings, research has
shown that the concentration of the
trypsin-2-α
1
-antitrypsin (T2-AAT) com-
plex to be elevated in patients with AP
and to correlate strongly with disease se-
verity (Hedström et al. 1994, 1996d), sug-
gesting that trypsinogen-2 may play a
more important role in the pathogenesis
of AP than previously believed. In addi-
tion, Kukor recently reported a possible
protective role of trypsinogen-2 under
pathological conditions (Kukor et al.
2003). The cause of these considerable
differences in the behavior of trypsino-
gen-1 and -2 during the pathogenesis of
AP still remains obscure.
2.4.5.3 Trypsinogen activation peptide
(TAP)
Trypsinogen activation peptides (TAP)
are highly-conserved amino-terminus
peptides released when trypsinogen is
activated to trypsin. Trypsinogen-2 liber-
ates one octapeptide (Guy et al. 1976),
whereas trypsinogen-1 liberates two
peptides: this same octapeptide and a
peptapeptide (Guy et al. 1978). Normal-
ly, they are degraded in the intestine by
enteric oligopeptidases (Guy et al. 1978).
Premature activation of trypsinogen
has been suggested as the pathogenetic
basis for AP, beginning within minutes
after exposure to the causative factor
(Steer 1998; Whitcomb 1999a), and re-
sulting in the formation of TAP. In itself
TAP seems to play no pathogenetic role,
but has been proposed to accurately re-
flect the rate of trypsinogen activation
(Hurley et al. 1988). Thus, TAP has been
suggested as a marker of disease severity
(Gudgeon et al. 1990) as it has a short
lifetime of about eight minutes in the
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circulation (Simpson et al. 1995) and is
secreted into the urine (Gudgeon et al.
1990). TAP’s concentrations should the-
oretically correlate with those of trypsin-
1-α
1
-antitrypsin (T1-AAT) and T2-AAT
complexes, but due to its rapid turnover,
TAP is difficult to measure in plasma.
TAP concentrations in plasma fluctuate,
whereas urinary TAP values reflect for-
mation over a longer time period and are
more stable. Intra-acinar activation of
trypsinogen has been implicated as the
key event in AP (Steer 1998), and TAP is
thought to originate entirely from acinar
cells. Some evidence of extrapancreatic
trypsinogen activation exists, but its role
in the pathophysiology of sever AP re-
mains unclear (Hartwig et al. 1999a,
1999b).
2.4.6 Protease inhibitors in acute
pancreatitis
2.4.6.1 Pancreatic secretory trypsin
inhibitor (PSTI)
The presens of a variety of protease in-
hibitors prevents the premature activa-
tion of pancreatic proenzymes within
the pancreas. In 1948, Kazal et al. initially
isolated the trypsin inhibitor PSTI (MW
6200), also referred to as TATI (tumor-
associated trypsin inhibitor) or SPINK1
(serine protease inhibitor, Kazal type 1)
(Pfützer et al. 2000; Stenman 2002). As
already mentioned, PSTI is a strong in-
hibitor of trypsin, acting as a first line of
defense in the pancreas in the case of
premature activation of trypsinogen
(Pubols et al. 1974; Rinderknecht 1986).
PSTI accounts for 0.1% to 0.8% of the
total amount of protein in pancreatic
juice, and is capable of inhibiting up to
20% of the potential trypsin activity
within the pancreas in the event that
trypsinogen becomes prematurely acti-
vated (Pubols et al. 1974). The PSTI/
trypsin ratio remains fairly constant,
since the concentration of trypsinogen
and PSTI parallel each other closely after
stimulation (Lasson et al. 1986b). The
complex formation with trypsin is tem-
porary, and trypsin is transferred to α
2
-
macroglobulin in plasma (Eddeland and
Ohlsson 1978b). Because of its small size,
PSTI is rapidly cleared from the circula-
tion; its half-life is approximately six
minutes (Marks and Ohlsson 1983). Sig-
nificant amounts of PSTI are also pro-
duced outside the pancreas (Stenman
2002), and normal levels of PSTI are
found even after a total pancreatectomy
(Halila et al. 1985). PSTI may act as an
acute phase protein, and severe infection
and tissue destruction raise concentra-
tions in serum and urine (Lasson et al.
1986a; Ogawa 1988). The gene that en-
codes PSTI contains an IL-6 responsive
element (Ohmachi et al. 1993), and in
hepatoma cells, IL-6 induces expression
(Yasuda et al. 1998). PSTI derived from
the liver likely increases the serum con-
centrations of PSTI in inflammatory dis-
eases (Yasuda et al. 1998; Stenman 2002).
2.4.6.2 Other protease inhibitors
The quantitatively dominant protease in-
hibitor in plasma is AAT. Synthesized in
the liver, AAT acts as an acute phase pro-
tein. Because of its relatively small size
(55kD), AAT diffuses into the extra vas-
cular space and inhibits released proteas-
es; its half-life is about 45 minutes (Ohls-
son 1971). The main inhibitory target of
AAT action is probably leukocyte elastase
(Beatty et al. 1980). AAT also inhibits
trypsin, and in AP, studies report eleva-
tions in both the T1-AAT and T2-AAT
complexes (Borgström and Lasson 1984;
Hedström et al. 1994; 1996c).
α
2
-macroglobulin is a large glyco-
protein that consists of four subunits
having a total MW of about 725 kD. It is
synthesized in hepatocytes and macro-
phages and is considered to be the most
important protease inhibitor since it is
capable of inhibiting all types of proteas-
es (Barrett and Starkey 1973). α
2
-mac-
roglobulin plays a key role in the defense
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against trypsin, and has the ability to take
over trypsin from the PSTI-trypsin com-
plex. Complexes between α
2
-macroglobu-
lin and trypsin are eliminated via the re-
ticuloendothelial system and hepatocytes
with a half-time of about ten minutes
(Laskowski and Kato 1980) (Fig. 1). In
severe AP, studies report lower α
2
-mac-
roglobulin levels than in mild AP, indi-
cating consumption of α
2
-macroglobu-
lin (Lasson and Ohlsson 1984). To date,
no assay has yet been developed to meas-
ure directly the complex of trypsin-1 or -
2 with α
2
-macroglobulin.
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Fig. 1. Trypsin metabolism in acute pancreatitis. After exposure to a trigger event (alcohol
or gallstone migration, etc.), the first phenomenon observed is a blockade of acinar secre-
tion leading to activation of trypsinogen to trypsin in the pancreatic acinar cells. Then,
trypsin leads to the activation cascade of other zymogens and autodigestion of the gland.
The inflammatory process leads to the leakage of pancreatic enzymes into the circulation.
PSTI acts as a first line of defense in the pancreas, and temporarily inhibits trypsin. When
the trypsin-PSTI complex leaks into the circulation, it comes to a very rapid dissociation,
and the trypsin released from the trypsin-PSTI complex is bound to α
2
-macroglobulin
and to α
1
-antitrypsin. The trypsin-α
2
-macroglobulin and trypsin-α
1
-antitrypsin complex-
es are rapidly eliminated from the circulation through the reticulo-endothelial system. A
small amount of the PSTI thus released is bound by the trypsin-α
2
-macroglobulin com-
plex, but the majority of the PSTI remains free. Trypsinogen released from the acinar cells
into the circulation is eliminated without marked activation in urine. TAP released from
acinar cells into the circulation is rapidly eliminated in urine.
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2.4.7 Hereditary pancreatitis
Acute pancreatitis may result from the
same genetic mutations that lead to
chronic pancreatitis. Hereditary pancrea-
titis is a genetic disorder with the auto-
somal-dominant inheritance pattern first
described in 1952 (Comfort and Stein-
berg 1952). Patients with hereditary pan-
creatitis develop attacks of AP similar to
those observed in connection with more
common causes, such as alcohol con-
sumption or gallstones. The attacks of
AP usually begin in childhood (Perrault
1994). In 1996, researchers identified a
mutation in the trypsinogen-1 gene that
causes hereditary pancreatitis. This sin-
gle point mutation results in the change
of arginin (Arg, R) to histidine (His, H)
at position 122, numbered R122H. This
mutation was originally referred to as
R117H on the basis of the chymot-
rypsinogen numbering (Whitcomb et al.
1996). This mutation is belived to elimi-
nate a trypsin hydrolysis site necessary to
the initiate autodigestion of trypsin
(Whitcomb 1999b). This causes a gain-
of-function by preventing the inactiva-
tion of prematurely activated trypsin.
Recently, several other mutations in the
trypsinogen-1 gene have been detected
in patients with hereditary pancreatitis.
The second most common is the N29I
mutation (older nomenclature N21I)
(Whitcomb 1999b), but the mechanisms
causing pancreatitis through this muta-
tion remains to be clarified. In addition,
a number of other rare mutations have
been identified (Whitcomb 2000).
Mutations in the PSTI gene are fairly
common in the general population and
are not associated with hereditary pan-
creatitis (Pfützer et al. 2000; Witt et al.
2000). Some have suggested that these
PSTI mutations modify disease, by low-
ering the threshold for development of
AP from other causes, but do not them-
selves cause AP (Pfützer et al. 2000).
These observations imply that intra-
pancreatic trypsinogen activation is a key
event in the pathogenesis and develop-
ment of AP.
2.5 Diagnosis of acute
pancreatitis
2.5.1 Clinical assessment
The diagnosis of AP relies on a combina-
tion of clinical evaluation and the use of
supportive laboratory and radiological
investigations (Steinberg and Tenner
1994). Diagnosis is not always straight-
forward, because the disease has a varia-
ble presentation and severity, and no es-
tablished standard for its diagnosis exists.
Usually, patients exhibit with mild-to-se-
vere epigastric pain, which in about 50%
of cases radiates to the back and flanks,
accompanied by nausea, vomiting, and
fever (Bradley 1993). In cases of atypical
presentation of the disease, diagnosis is
more difficult. In autopsy studies, up to
42% of AP patients were undiagnosed in
life (Wilson et al. 1988; Lankisch et al.
1991; Appelros and Borgström 1999).
One reason for this could be that only
8% to 13% of undiagnosed patients ex-
hibited abdominal pain. Currently, more
liberal use of CT is recommended in the
evaluation of patients with atypical pres-
entation, which increases diagnostic ac-
curacy.
2.5.2 Laboratory diagnostics
2.5.2.1 Amylase and lipase
The measurement of amylase has been
the cornerstone of the diagnosis of AP
since 1929, when its use and significance
in the diagnosis of AP was demonstrated
(Elman 1929). Amylase is not specific to
the pancreas, and any intra-abdominal
inflammatory event can lead to an eleva-
tion in amylase activity (Salt and
Schenker 1976). Derived from acinar
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cells, serum amylase levels increase with-
in 2 to 12 hours of the onset of symp-
toms of AP, and generally return to nor-
mal over the next 3 to 5 days (Agarwal et
al. 1990). Amylase alone cannot be used
in the diagnosis of AP, because up to
19% of AP patients show normal amyla-
se values on admission (Clavien et al.
1989b). Furthermore, several diseases
such as intestinal obstruction, perforated
ulcer, ruptured ectopic pregnancy and
mesenteric thrombosis may raise amyla-
se levels (Salt and Schenker 1976). Uri-
nary amylase activity rises somewhat lat-
er than that of serum, but are otherwise
comparable, and neither serum nor uri-
nary amylase levels correlate with disease
severity (Moossa 1984).
Lipase is synthesized mainly in the
pancreatic acinar cells, but can also be
synthesized in other tissues such as the
liver and stomach (Clavien et al. 1989a).
It usually rises 4 to 8 hours after the on-
set of AP and will normalize within 8 to
14 days. Wide variations in sensitivity
and specificity for serum lipase have
been reported, probably due in part to
the use of various assay methods and
thresholds (Patt et al. 1966; Clavien et al.
1989a). Because, lipase levels remain ele-
vated longer than those of amylase, re-
searchers have suggested that the com-
bined use of amylase and lipase would be
useful if there is a delay between symp-
tom onset and hospitalization. Further-
more, many normoamylasemic patients
with AP might be diagnosed (Clavien et
al. 1989a). The specificity of lipase is
generally no higher than that of amylase,
and many intra-abdominal inflammato-
ry events can also lead to elevated lipase
levels (Patt et al. 1966).
2.5.2.2 Trypsinogen
Due to the limitations in accuracy of
amylase and lipase use in the diagnostics
of AP, other markers have been evaluat-
ed. Serum and urinary trypsinogen-2
measurements, as well as the measure-
ment of the complex of T2-AAT, have
proved useful as diagnostic markers of
AP (Itkonen et al. 1990; Hedström et al.
1994, 1996c; 1996d; Kemppainen et al.
1997a). A recently developed rapid dip-
stick test for trypsinogen-2 in urine has
been found to be a sensitive (Hedström
et al. 1996b) and a rather specific
(Kemppainen et al. 1997b) diagnostic
marker for AP. However, trypsinogen-2
is not specific to AP and elevated serum
trypsinogen-2 concentrations have occa-
sionally been observed in patients with
abdominal pain, and especially in pa-
tients with renal failure, obstructive bil-
iary disease, gastric or colorectal cancer
(Hedström et al. 1994, 1996a).
2.5.2.3 Other laboratory methods
Several other markers have been evaluat-
ed as diagnostic tests for AP, including
serum elastase (Flamion et al. 1987),
phospholipase A
2
 (Schröder et al. 1980),
pancreas-specific protein (known also as
procarboxylpeptidase B) (Chen et al.
1994), and pancreatic isoamylase (Clave
et al. 1995), but appear to offer no ad-
vantage over amylase and lipase.
2.5.2.4 Imaging
Contrast-enhanced computed tomogra-
phy (CE-CT) has been used for nearly 20
years and is the most important imaging
modality for the evaluation of patients
with AP (Kivisaari et al. 1984; Balthazar
1989). For patients with a clear case of
AP, CT imaging is largely unnecessary,
but if a patient’s clinical presentation is
atypical or the enzyme levels are not di-
agnostic, CE-CT should be used without
hesitation to avoid overlooking any pos-
sible cases of AP. CE-CT may, however,
be normal in up to 30% of patients with
mild AP (Balthazar et al. 1985; Moulton
1991). CE-CT should also be used later
during hospitalization to identify any
potential complications (Merkle and
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Görich 2002). Limited availability, high
costs and potential side effects, however,
limits the use of CE-CT as a primary di-
agnostic tool of AP (London et al. 1989;
Carmona-Sanchez et al. 2000). Recent
reports indicate that the intravenous
contrast medium does not aggravate the
course of AP (Hwang et al. 2000; Uhl et
al. 2002a). Currently, a CT scan without
intravenous contrast medium is pre-
ferred in the early phase of the disease to
avoid damaging renal function. Magnetic
resonance imaging (MRI) is comparable
to CT in its capacity to diagnose AP (Pii-
ronen et al. 2000).
Ultrasonography is the basic imaging
method in patients with acute abdomen,
but its utility in AP is limited. In the ini-
tial phase of the disease, a swollen pan-
creas may be detected, but due to over-
laying bowel gas, the gland cannot be
visualized in 30% to 40% of patients
(Silverstein et al. 1981). It is, however,
useful in evaluating the biliary tract for
gallstones and biliary obstruction as well
as in the follow-up of fluid collections
and pseudocysts (Merkle and Görich
2002).
2.6 Severity assessment of
acute pancreatitis
2.6.1 Factors related to severity in
acute pancreatitis
In the majority of cases, AP is a mild
self-limiting disease with a mortality of
less than 2% (Beger et al. 2001). Howev-
er, about 20% of all cases develop severe
disease, and despite considerable im-
provements in treatment, mortality re-
mains between 15% and 25% (Tsiotos et
al. 1998; Beger and Isenmann 1999; Isen-
mann et al. 2001a), reaching up to 40%
if pancreatic necrosis is infected (Beger
et al. 1986). It has become increasingly
clear that severe AP progresses in two
phases. The first two weeks are charac-
terized by a systemic inflammatory re-
sponse syndrome (SIRS) due to the re-
lease of various inflammatory mediators
(Norman 1998). In some studies, about
50% of the deaths in severe AP occur in
this period, as a result of massive SIRS
leading to multiple organ dysfunction
syndrome (MODS) with no apparent
bacterial infection (McKay et al. 1999).
However, other studies report no early
mortality (Gloor et al. 2001). One possi-
ble explanation for this striking discrep-
ancy may be the standard of intensive
care treatment. Moreover, it points to the
importance of early recognition of severe
disease and the focused management of
these patients in specialized centers. Lat-
er, in the second phase of the disease,
mortality most often results from septic
MODS caused by secondary infection of
pancreatic or peripancreatic necrosis
(Gloor et al. 2001), which has been re-
ported in up to 70% of patients with se-
vere AP (Beger et al. 1986).
The reason why some patients devel-
op a severe necrotizing form of AP is un-
known. Some evidence suggests that
protease-antiprotease imbalance and
proinflammatory/antiinflammatory
mechanisms are crucial in the develop-
ment of severe AP, leading to the activa-
tion of cascade systems such as the com-
plement and coagulation cascades
(Glasbrenner and Adler 1993). Other ex-
perimental and clinical evidence indi-
cates that the duration of the causative
mechanisms may affect severity (Wilson
et al. 1988; Rünzi et al. 1993). Rinderk-
necht proposed in 1988 the widely ac-
cepted theory of excessive leukocyte
stimulation activating of different in-
flammatory mediators, leading to pul-
monary, renal, and hematological com-
plications (Rinderknecht 1988).
The development of severe AP and
the risk of life-threatening complications
appear multifactorial. Genetically, deter-
mined predisposing factors that cause
variable responses to the same biological
stimuli may affect disease severity (Rind-
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erknecht 1994). Advanced age, comor-
bidity, and a history of continuous medi-
cation also influence overall outcome
(Larvin 1996; Halonen et al. 2000) as
well as does the initial treatment in the
early phase of the disease. This is empha-
sized in a recent study showing that pa-
tients with severe AP admitted to the in-
tensive care unit after a delay of more
than 24 hours run a four-fold risk of dy-
ing (Brivet et al. 1999).
2.6.2 Atlanta severity classification
A clinically based classification system
for AP was established in the Interna-
tional Symposium on Acute Pancreatitis
in Atlanta, Georgia, in 1992. According
to this classification, severe AP is associ-
ated with organ failure and/or local com-
plications such as necrosis, abscesses, or
pseudocysts. Furthermore, the accumu-
lation of three or more Ranson criteria,
or eight or more Acute Physiology and
Chronic Health Evaluation II (APACHE
II) points, characterizes severe AP (Brad-
ley 1993). The Atlanta classification has
rapidly become the standard in clinical
research, enabling more rational com-
parisons between and within trials. Criti-
cism of the Atlanta severity classification
system is growing, however, because it is
retrospective, the duration of organ fail-
ure is unspecified, and because local
complications do not seem to increase
mortality (Isenmann et al. 2001b).
2.6.3 Early prediction of severity
Within the first 48 hours there is a thera-
peutic window when specific treatment
alternatives may alter a patient’s out-
come. Beneficial results have been ob-
tained with the early management of pa-
tients correctly classified as severe, in
intensive care units, with early ERCP in
gallstone-induced disease, and prophy-
lactic antibiotics (Sainio et al. 1995; Briv-
et et al. 1999; Schmid et al. 1999b; Shar-
ma and Howden 1999; Nordback et al.
2001). Conversely, reliable exclusion of
patients with severe AP helps to avoid
unnecessary use of invasive and other-
wise costly procedures in mild cases,
thereby facilitating optimal use of limit-
ed health care resources. The problem in
early phase severity assessment is the
lack of accurate predictors. Many at-
tempts have been made to create scoring
systems and laboratory markers for the
early severity assessment of AP during
the past 20 years, but the methods availa-
ble are generally considered unsatisfacto-
ry (Dervenis 2001).
2.6.4 Clinical assessment
Before the 1970s, the only tool available
for evaluating patients with AP was clini-
cal assessment. The clinician is, however,
poor at predicting the severity of AP on
admission, and fails to identify up to
two-thirds of patients, who eventually
develop complications or die (McMahon
et al. 1980; Wilson et al. 1990). With
longer follow-up (48 hours), clinical as-
sessment becomes more reliable, ap-
proaching multifactorial scoring systems
(Larvin and McMahon 1989). Although
associated with severe disease, clinical
symptoms such as Grey Turner’s and
Cullen’s signs (Dickson and Imrie 1984)
are relatively rare and should not be used
as staging criteria for AP (Lempinen and
Schröder 1986; Büchler 1991). While ac-
curate clinical assessment is of great im-
portance for routine patient manage-
ment, its main drawback is its
unreliability in initial severity assess-
ment. Furthermore, it is subjective and
dependent on the observer’s experience
(Wilson et al. 1990).
2.6.5 Multifactorial scoring systems
In the mid-1970s, John Ranson in New
York published the concept of combin-
ing different parameters to produce a
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multifactorial scoring system identifying
a high-risk group of AP patients (Ran-
son et al. 1974). Some years later, the
Glasgow group introduced a European
version of scoring systems (Imrie et al.
1978; Osborne et al. 1981). The Ranson
score comprises 11 biochemical criteria,
whereas the Glasgow score combines 8
parameters. In both scoring systems,
three or more fulfilled criteria indicate
severe disease. Both scoring systems are
equally effective predictors of mortality
(Larvin and McMahon 1989), but their
drawback is the need for an observation
period of 48 hours to judge all parame-
ters. Furthermore, the scores cannot be
measured serially. This time lag of 48
hours is considered too long for early
therapeutic decisions, and in a recent
meta-analysis the Ranson score was
found to have poor predictive power (De
Bernardinis et al. 1999). These two scor-
ing systems are pancreatitis-specific in
contrast to the APACHE II system
(Knaus et al. 1985). This has been com-
pared prospectively to the Ranson and
Glasgow scoring methods and found to
be equally good at 48 hours (Larvin and
McMahon 1989; Wilson et al. 1990).
APACHE II has an advantage in that it
can be determined at admission and re-
calculated daily. However, it is cumber-
some and time-consuming, and there-
fore not routinely used in clinical
practice (Toh et al. 2000).
2.6.6 Radiological imaging
CT-based scoring systems for the staging
of AP, such as the Schröder (Schröder et
al. 1985) and Balthazar (Balthazar et al.
1985) scores, show prognostic value al-
ready within the first 24 hours after ad-
mission (Kivisaari et al. 1983; Schröder
et al. 1985; Kivisaari et al. 1991). In the
Atlanta severity classification, CE-CT de-
fines pancreatic necrosis. If pancreatic
tissue enhancement is less than 50
Houndfield’s units (HU) in more than
30% of the pancreas or comprises an
area larger than 3 cm, it is considered in-
dicative of pancreatic necrosis and severe
AP. MRI has shown no advantage over
CE-CT in staging AP (Lecesne et al.
1999), its availability is limited, and the
scanning time long. However, it involves
no radiation.
2.6.7 Biochemical markers
Significant interest has grown in the de-
velopment of reliable biochemical mark-
ers that reflect the severity of AP in an
early phase of the disease. Various mark-
ers have been reported to have prognos-
tic value in AP (Larvin 1996; Triester and
Kowdley 2002; Yadav et al. 2002), but
most of them must be considered experi-
mental, due to lack of clinically useful
assay methods available on a 24 hour ba-
sis. These markers can be subdivided
into those indicating activation of in-
flammation, those correlating to the ex-
tent of pancreatic injury, and those
measuring activation peptides that re-
flect the proteolytic insult.
2.6.8 Markers of inflammation
2.6.8.1 C-reactive protein (CRP)
CRP is an acute phase reactant discov-
ered in 1930 (Tillett 1930) and synthe-
sized by hepatocytes (Pepys 1981). It is a
non-specific marker of inflammation
whose synthesis is induced by the release
of interleukins 1 (IL-1) and IL-6, and is
the most widely used predictor of severi-
ty in AP (Puolakkainen et al. 1987; Ne-
optolemos et al. 2000; Pezzilli et al.
2000). However, while useful in the fol-
low-up of the disease, there is a 48-to 72-
hour delay until peak values are reached,
which limits its use for the early evalua-
tion of the severity of AP (Puolakkainen
et al. 1987; Neoptolemos et al. 2000).
Multiple cut-off levels have been used in
the literature to predict severe AP; pres-
ently a level of 150 mg/ml is accepted as
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the most accurate (Dervenis et al. 1999).
In a recent European multicenter study,
the sensitivity, specificity, positive pre-
dictive value (PPV), and negative predic-
tive value (NPV) 48 hours after admis-
sion were 86%, 61%, 37%, and 94%
respectively, and the positive likelihood
ratio (PLR) was 2.2 (Neoptolemos et al.
2000). The advantages of CRP are that it
is easy to measure, cheap and widely
available.
2.6.8.2 Cytokines
Proinflammatory cytokines are consid-
ered important in the pathogenesis of se-
vere AP. IL-6 is the key mediator for
acute phase protein synthesis in the liver
(Pezzilli et al. 1995). Some suggest that
IL-6 is an accurate marker of severity in
the early phase of the disease (Heath et
al. 1993; Pezzilli et al. 1995; Inagaki et al.
1997), distinguishing between severe and
mild AP with an 86% to 100% sensitivity
and a 71% to 100% specificity (Heath et
al. 1993; Pezzilli et al. 1995; Chen et al.
1999a). Peak concentrations of IL-6 are
reached 24 to 48 hours before those of
CRP, which is a major advantage (Mess-
mann et al. 1997). A rapid assay to deter-
mine the serum concentrations of IL-6 is
available for routine use (Pezzilli et al.
1995), and a recent report suggests the
combined use of lipase and IL-6 for di-
agnosis and prognosis in emergency set-
tings (Pezzilli et al. 1999). This rapid as-
say is, however, expensive.
Interleukin-8 (IL-8) is also an inflam-
matory cytokine whose primary target
cell is the neutrophil, where it causes the
degranulation and release of enzymes
such as elastase (Gross et al. 1992). Circu-
lating levels of IL-8 and IL-6 change in
closely similar patterns in AP (Gross et al.
1992; Pezzilli et al. 1995; Chen et al.
1999a), and IL-8 also correlates with the
clinical course of the disease (Gross et al.
1992). In ERCP-induced pancreatitis, IL-8
increased even earlier than did IL-6
(Messmann et al. 1997).
Other cytokines have been evaluated
as well. Contradictory reports have been
published on interleukin-10 (IL-10), a
cytokine that inhibits the release of
proinflammatory cytokines by macro-
phages. In one study, lower serum con-
centrations were observed in patients
with severe AP than in patients with
mild AP (Pezzilli et al. 1997), but results
have been contradictory (Chen et al.
1999b). In an experimental study, with
knockout-mice for IL-10 (IL-10-/-), AP
was more severe in IL-10-/- mice than in
wild-type animals (Gloor et al. 1998),
suggesting that IL-10 exerts a protective
role in experimental AP.
IL-1 is produced during acute and
chronic inflammation, and showed no
correlation with the severity of AP
(McKay et al. 1996), whereas the release
of tumor necrosis factor (TNF), a mac-
rophage-derived cytokine considered im-
portant during injury and sepsis (Beutler
and Cerami 1987), was more strongly el-
evated in severe than in mild AP (McKay
et al. 1996; Chen et al. 1999a). However,
others have presented contradictory re-
ports, suggesting that the measurement
of TNF is of no clinical value in assessing
the severity of AP (Paajanen et al. 1995).
2.6.8.3 Procalcitonin (PCT)
Procalcitonin (PCT), which is the pre-
cursor of calcitonin synthesized in the
thyroid, is a new serum marker reported
to be associated with severe infection
and inflammation (Assicot et al. 1993;
Hensel et al. 1998). Elevated levels of
PCT have been reported after ERCP-in-
duced pancreatitis (Oezcueruemez-Por-
sch et al. 1998). Rau et al. proposed that
PCT could be a valuable tool for the
noninvasive detection of bacterial con-
tamination of pancreatic necrosis (Rau
et al. 1997). In contrast, Müller et al. re-
cently reported that PCT was not suita-
ble for early prediction of infected pan-
creatic necrosis (Müller et al. 2000). In a
study by Kylänpää-Bäck et al., higher
24
PCT concentrations were observed on
admission in patients with severe AP
than in patients with mild AP, and fur-
thermore, at 12 hours and 24 hours after
admission, PCT concentrations were
markedly higher in those patients with
severe AP who subsequently developed
organ failure (Kylänpää-Bäck et al.
2001b). A rapid semiquantitative PCT
test showed promising results as an early
screening method for severe AP (Kylän-
pää-Bäck et al. 2001a).
2.6.8.4 Other markers of inflamma-
tion
Several other markers of immune re-
sponse have been evaluated as severity
markers in AP, including polymorpho-
nuclear elastase and serum amyloid A. In
severe AP, neutrophils cumulate in the
pancreas, producing elastase that de-
grades the extracellular matrix (Wereszc-
zynska et al. 1998). Elastase concentra-
tions in plasma have been found to be
higher in severe than in mild AP (Uhl et
al. 1991), and moreover, neutrophil
elastase increases earlier than does CRP.
Serum amyloid A is a non-specific mark-
er of inflammation, acting as an acute
phase reactant, which has also been eval-
uated in the severity assessment of AP. In
a study by Mayer et al. (2000) serum
amyloid A predicted the severity better
than did CRP during the first 24 hours
after hospitalization, exhibiting a sensi-
tivity of 67%, a specificity of 70%, and
an NPV of 89% respectively. This study
suggested serum amyloid A to be clini-
cally useful in the early prediction of se-
verity in AP. A study by Pezzili et al.
(2000) supported these findings by
showing that serum amyloid A is more
sensitive than is CRP during the first 24
hours in predicting severity. However,
CRP predicts pancreatic necrosis (prov-
en by CT or surgery) more accurately
than does serum amyloid A (Pezzilli et
al. 2000; Rau et al. 2000).
2.6.9 Markers of pancreatic injury
2.6.9.1 Trypsinogen-2
In AP, the inflammatory process leads to
the leakage of pancreatic enzymes into
circulation. Trypsinogen-2 has been
shown to correlate with the severity of
the disease (Itkonen et al. 1990; Hed-
ström et al. 1994, 1996c, 1996d; Kemp-
painen et al. 2000). In a study by Hed-
ström et al., (1996d) urine trypsinogen-2
showed a sensitivity of 68%, a specificity
of 80%, a PPV of 62%, an NPV of 84%
and a PLR of 3.8, respectively. In addi-
tion, a rapid dipstick method for the
measurement of trypsinogen-2 in urine,
which can be used as a screening test for
AP, has been developed (Kylänpää-Bäck
et al. 2000).
2.6.9.2 Trypsin-2-α
1
-antitrypsin
(T2-AAT)
The T2-AAT complex levels in serum
have been shown to correlate with the
severity of AP (Hedström et al. 1996c;
Kemppainen et al. 2000), and over the
initial 12 to 24 hours after admission, it
predicts severity more accurately than
does CRP (Hedström et al. 1996c).
Though promising, these results require
the confirmation and development of a
more rapid assay to make it clinically
useful.
2.6.9.3 Pancreatic secretory trypsin
inhibitor (PSTI)
In AP, serum PSTI has shown conflicting
results regarding its use as a severity
marker (Ogawa et al. 1980; Lasson and
Ohlsson 1984; Satake et al. 1988;
Hjelmqvist et al. 1989). However, in a re-
cent study comparing serum PSTI with
CRP, PSTI appeared a better earlier
marker of severity than did CRP (Pezzilli
et al. 1994). Elevated levels have also
been observed in the urine of patients
with pancreatitis (Eddeland and Ohlsson
1978a; Kitahara et al. 1980), and the pos-
sible use of urinary PSTI in the severity
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assessment of AP should also be evaluat-
ed; these results require confirmation.
2.6.9.4 Phospholipase A
2
 (PLA2)
PLA2 is a key enzyme in arachidonic
acid metabolism, generating precursors
of prostaglandins and leukotrines, which
are important elements in many biologi-
cal responses including inflammation.
Of the different isoenzymes described,
group II PLA2 shows correlation with
disease severity in AP (Grönroos and
Nevalainen 1992; Nevalainen et al. 1993).
The activity pattern of PLA2 resembles
that of CRP (Puolakkainen et al. 1987).
In a recent study by Mayer et al., group
II PLA2 concentrations in serum were
higher in patients with infected pancre-
atic necrosis than in those with sterile
necrosis (Mayer et al. 1998). Additional-
ly, group II PLA2 correlated with the ap-
pearance of SIRS in severe AP (Hietaran-
ta et al. 1999). At present, however, the
cumbersome assay method limits its
clinical use.
2.6.10 Activation peptides
2.6.10.1 Trypsinogen activation pep-
tide (TAP)
In 1988, Hurley et al. created antibodies
against the C-terminal end of the activa-
tion peptides (Hurley et al. 1988), and
the first clinical study, published in 1990
(Gudgeon et al. 1990), showed that high
levels of TAP in urine correlated with the
severity of the attack. In about 30% of
patients with AP, no TAP appeared in
urine, suggesting that it cannot be used
for the diagnosis of AP. TAP also faild to
increase in mild post-ERCP pancreatitis
(Banks et al. 1996). The original findings
have been confirmed (Tenner et al. 1997;
Neoptolemos et al. 2000). In a study by
Neoptolemos et al., urinary TAP provid-
ed good severity prediction 24 hours af-
ter admission, showing a sensitivity of
68%, a specificity of 74%, a PPV of 44%,
an NPV of 89%, and a PLR of 2.6, re-
spectively. TAP values in the plasma of
patients with AP also correlate well with
the severity of the disease on admission,
but prognostic accuracy declines rapidly
(Kemppainen et al. 2001). TAP is be-
lieved to be specific to the pancreas. In a
review article, Frossard emphasised that
TAP has the capability of differentiating
between severe and mild AP in an early
phase of the disease, which is clinically
favourable since other methods are not
yet useful (Frossard 2001). Windsor,
however, found that the measurement of
TAP provides no additional information
regarding the severity assessment than
do the results of other markers (Windsor
2000). A limitation of TAP is the en-
zyme-linked immunosorbent assay (ELI-
SA), which takes several hours and is not
widely available. An automated assay
method is needed if TAP is to be used in
clinical practise.
2.6.10.2 Other activation peptides
In addition to TAP, phospholipase A
2
activation peptide (PLAP) and procar-
boxypeptidase B activation peptide (CA-
PAP) have been evaluated as severity
markers in AP (Heath et al. 1995). PLAP
is released from pancreatic PLA2 by
trypsin, and consists of seven amino ac-
ids. Urinary PLAP levels correlated with
disease severity in a study by Heath et al.,
TAP and PLAP peak values were ob-
served 12 and 24 hours after symptom
onset, preceding the increase of IL-6 and
CRP (Heath et al. 1995). A recent study
by Mayer et al., confirmed these results
(Mayer et al. 2000). CAPAP is a large ac-
tivation peptide composed of an 81-ami-
no acid polypeptide released from pro-
carboxypeptidase B. CPAP is stable in
serum as well as in urine, and three ret-
rospective studies have shown that it dis-
criminates well between severe and mild
AP (Appelros et al. 1998; Appelros et al.
2001; Müller et al. 2002). In a study by
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Appelros et al., the sensitivity was 92%,
specificity 89%, PPV 69%, NPV 98%,
and PLR 8.3, within 72 hours of symp-
tom onset (Appelros et al. 2001).
2.7 Endoscopic retrograde
cholangiopancreatography
(ERCP)
2.7.1 Post-ERCP pancreatitis
One major disadvantage when studying
the pathogenesis of AP in humans is the
delay between the onset of symptoms
and admission to the hospital. As a re-
sult, little data on the initiation phase of
AP is available to describe exactly the
time course of pancreatic enzymes, pro-
tease inhibitors, cytokine release, and
acute phase response in humans. Post-
ERCP pancreatitis is the most common
and most feared complication of ERCP
(Sherman 1994; Freeman et al. 1996;
2001). It is a useful model to study the
early phase of AP, as the time of onset is
precisely known and samples can also be
obtained before the disease breaks out.
Other ERCP-related complications in-
clude haemorrhage, perforation, cholan-
gitis, cholecystitis, bile leakage, cardiop-
ulmonary complications, and pseudocyst
infection (Sherman 1994; Freeman et al.
1996).
In recent reports, the incidence of
post-ERCP pancreatitis has varied be-
tween 3.3% and 10%, with most cases
being mild (Freeman et al. 1996; Kemp-
painen et al. 1997a; Freeman et al. 2001;
Christoforidis et al. 2002). However, in a
recent Danish report, 20 cases of severe
pancreatitis and 7 deaths due to post-
ERCP pancreatitis, were recorded during
a period of 4½ years (Trap et al. 1999),
thus demonstrating the risks of the pro-
cedure. Today neither consensus as to the
pathogenesis or risk factors for post-
ERCP pancreatitis, nor “gold standard”
of its definition exist. The year 1991 saw
an attempt to reach consensus on the
criteria of post-ERCP pancreatitis (Cot-
ton et al. 1991), but the definition and
severity grading still vary among au-
thors.
Attempts to prevent post-ERCP pan-
creatitis have been made using technical
measures and pharmacological prophy-
laxis without much success (Testoni
2003). In a recent meta-analysis, the pro-
tease inhibitor gabexate mesilate and so-
matostatin were reported of benefit in
preventing ERCP-induced pancreatitis
(Andriulli et al. 2000). In addition, pro-
phylactic antibiotics and IL-10 have been
reported to reduce the risk of post-ERCP
pancreatitis (Deviere et al. 2001; Räty et
al. 2001).
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3 PRESENT INVESTIGATION
3.1 Aims of the study
The main purpose of the present clinical
study was to evaluate new markers of the
severity of AP and to gain insight into
the pathogenesis and characteristics of
AP in the early phase of the disease. The
specific aims were as follows:
1. To assess the prognostic value of uri-
nary TAP in patients with AP within
24 hours of symptom onset using a
new, more rigorous definition of se-
verity (I).
2. To evaluate the accuracy of urinary
trypsinogen-2 against that of urinary
TAP and of serum CRP in their abili-
ty to differentiate between patients
with severe and mild AP in the early
phase of the disease (II).
3. To assess the ability of a novel rapid
urinary trypsinogen-2 dipstick test
with a 2000 mg/l cut-off in predicting
the development of severe AP (III).
4. To characterize sequential changes in
the concentrations of trypsinogen-1,
trypsinogen-2, the complexes of
trypsin-1, and trypsin-2 with AAT,
TAP and PSTI in the serum and urine
of patients with AP with respect to
the clinical course of the disease (IV).
5. To clarify early sequential changes in
the concentrations of serum trypsino-
gen-1, trypsinogen-2, and the com-
plexes of trypsin-2 with AAT and PSTI
in AP by using ERCP-induced pancre-
atitis as a model of AP (V).
3.2 Materials and methods
3.2.1 General
In total, 967 patients admitted to Helsin-
ki University Central Hospital (I-V),
Glasgow Royal Infirmary (I), and South-
ampton General Hospital (I) were in-
cluded in this study (Table 1). In Study I,
patients with AP had to fulfil the follow-
ing inclusion criteria before being ac-
cepted for the study: admission to the
hospital within 24 hours of symptom
onset, over 18 years of age, no evidence
of chronic pancreatitis, no previous pan-
creatic surgery or surgery for pancreatitis
other than cholecystectomy. Patients
with no more than 72 hours of acute ab-
dominal symptoms were included in
Studies II to IV.
Table 1. Patients
n F/M Age* Study
Patients with abdominal pain 32 15/17 54 (25 to 87) IV
Patients with mild AP 219 96/123 55 (20 to 92) I, II, III, IV
Patients with severe AP 57 15/42 52 (29 to 84) I, II, III, IV
ERCP patients 659 374/285 65 (20 to 98) V
Totaling 967 500/467 57 (20 to 98)
*= mean and range
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3.2.2 Patients with acute abdomen
of nonpancreatic origin
This group consisted of 32 patients ad-
mitted to the emergency unit at Helsinki
University Central Hospital between Au-
gust 1997 and August 1998 with symp-
toms similar to those of AP (IV). AP was
excluded in this group of patients by re-
peated laboratory sampling, clinical fol-
low-up, and imaging procedures. The fi-
nal diagnoses of the patients with acute
abdomen of nonpancreatic origin are
listed in Study IV, Table I.
3.2.3 Patients with mild acute
pancreatitis
These 219 patients were admitted to the
emergency unit at Helsinki University
Central Hospital between August 1997
and August 2000 (I, II, III, IV), and to
the emergency units at the Glasgow Roy-
al Infirmary and Southampton General
Hospital between August 1999 and Au-
gust 2000 (I).
3.2.4 Patients with severe acute
pancreatitis
The 57 patients with severe AP were ad-
mitted to the emergency unit at Helsinki
University Central Hospital between Au-
gust 1997 and August 2000 (I, II, III, IV)
and to the emergency units at the Glas-
gow Royal Infirmary and Southampton
General Hospital between August 1999
and August 2000 (I). The diagnosis and
severity of AP was categorized on the ba-
sis of the criteria described in sections
3.2.6.1 and 3.2.6.2.
3.2.5 ERCP patients
A total of 659 patients underwent 897
ERCP procedures at the Second Depart-
ment of Surgery at Helsinki University
Central Hospital between December
2000 and July 2002. In study V, all pa-
tients suffering from post-ERCP pancre-
atitis (50 patients) were included while
61 randomly-selected patients without
post-ERCP pancreatitis served as con-
trols (V).
3.2.6 Diagnostic criteria and sever-
ity assessment of acute pancreatitis
3.2.6.1 Diagnostic criteria
AP was diagnosed if the patients had a
clinical presentation consistent with AP
and a plasma or serum amylase greater
than three times the upper reference lim-
it, or confirmation of pancreatitis by CT
or ultrasonography in patients with nor-
mal or marginally elevated serum amyla-
se concentrations (300 to 900 U/L). Ab-
dominal pain, vomiting, fever, tachy-
cardia, increased tenderness, rebound,
distension, bowel paralysis, Grey Turn-
er’s sign, or Cullen’s sign were considered
clinical signs of AP.
The diagnosis of ERCP-induced AP
was based on an increase of amylase in
serum greater than three times the upper
reference limit within 24 hours, com-
bined with persistent abdominal pain for
at least 24 hours after the procedure.
3.2.6.2 Severity assessment
The severity of AP was categorized retro-
spectively by the clinically-based classifi-
cation of the 1992 Atlanta symposium
(Bradley 1993) (II–V). According to the
Atlanta classification, mild AP is associ-
ated with minimal organ dysfunction
and an uneventful recovery, while AP is
classified as severe if systemic or local
complications or both are present (Brad-
ley 1993). A more rigorous definition of
severity was used in Study I than the
original Atlanta classification proposes.
Those patients who suffered transient
organ failure that resolved in 48 hours
were classified as mild, and only those
with failure of one or more organs that
persisted for more than 48 hours were
classified as severe.
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3.2.7 Multifactorial scoring systems
The appropriate parameters required for
the calculation of APACHE II score,
Glasgow score, Ranson score, and Ber-
nard/MODS score were measured. The
most abnormal values were used to cal-
culate the APACHE II score (I, II, III).
The Glasgow and Ranson scores were
calculated using values obtained during
the first 48 hours in the hospital (I, II).
Organ failure was determined in Study I
using the Bernard/MODS score (Mar-
shall et al. 1995), as modified for use in
AP, where a score of two in any system
closely approximates the definition of se-
vere AP according to the Atlanta classifi-
cation. The score provides the means to
grade the intensity of dysfunction of six
organ systems: the respiratory, the hepat-
ic, the renal, the cardiovascular, the he-
matologic, and the central nervous sys-
tems. Disturbance of hepatic function
was disregarded because of the com-
pounding effects of biliary disease.
3.2.8 Samples
In Study I, blood and urine samples were
taken on admission to the hospital in all
patients with suspected AP, and further
blood and urine samples were obtained
12 and 24 hours after admission in pa-
tients meeting the inclusion criteria.
Plasma and urine samples were stored at
–70°C until analysis.
In Studies II and IV, blood and urine
samples were obtained from each patient
on admission to the hospital in the
emergency unit, then every 12 hours for
the first 48 hours, and then daily from
day 3 to 5. Serum and urine samples
were stored at –70°C (Study II) and in
–20°C (Study IV) until analyzed.
The urine samples in Study III were
obtained on admission, and 24 hours
thereafter in the emergency department.
The samples were stored at –20°C until
tested with the strip and measured quan-
titatively.
In the ERCP Study (V), serial blood
samples were obtained before the proce-
dure, and then 2, 6, and 24 hours after,
and then every morning thereafter as
long as the patient was hospitalized. All
samples were stored at –70°C until ana-
lyzed.
The storage conditions and age of
the samples have no impact on the se-
rum concentrations of trypsinogen;
however, in the urine samples, the con-
centrations of trypsinogen, decrease to
some extent over the years, especially at
–20ºC.
3.2.9 Laboratory tests
All samples for the TAP assay were sent
to one laboratory (Biotrin International
Ltd., Mount Merrion, Dublin, Ireland).
A modified solid-phase enzyme immu-
noassay was used for urinary and serum
TAP measurements based on the compe-
tition between free and immobilized
peptide binding to an antibody to TAP,
as described earlier (Hurley et al. 1988;
Neoptolemos et al. 2000). In brief, the
assay uses a carboxy-terminus-specific
antibody to TAP raised in rabbits, pro-
duced by coupling the amino terminus
of the conserved pentapeptide of TAP to
thyroglobulin. Calibrator or sample and
anti-TAP antibody are sequentially add-
ed to microwells coated with TAP pep-
tide-carrier protein. After incubation, a
biotinylated second antibody, streptavi-
din-horseradish peroxidase, and tetram-
ethyl-benzidine are sequentially added.
The amount of antibody bound to the
solid phase is measured at 450 nm. The
detection limit of the assay was 1.8
nmol/L, the intra-assay variation, 12%,
and inter-assay variation, 14% (I, II, IV).
The concentrations of trypsinogen-1
and -2 in serum and urine, and of T1-
AAT and T2-AAT in serum were deter-
mined by time-resolved immunofluoro-
metric assays (IFMA) (II, IV, V). The
reference intervals in serum were 5.6 to
30
69 µg/l for trypsinogen-1, 18 to 90 µg/l
for trypsinogen-2, 8.9 to 33 µg/l for T1-
AAT, and 2.3 to 12 µg/l for T2-AAT
(Itkonen et al. 1990; Hedström et al.
1999, 1994). The detection limit of
trypsinogen-2 was 0.3 µg/l and for
trypsinogen-1, 0.1 µg/l (Itkonen et al.
1990). The concentration of PSTI was
determined by IFMA as previously de-
scribed; its detection limit was 0.05 µg/l
and reference range 2 to 15 µg/l (Osman
et al. 1993) (IV, V).
The urinary trypsinogen-2 dipstick
test Actim Pancreatitis (Medix Biochem-
ica, Kauniainen, Finland) is based on the
immunochromatographic principle de-
scribed previously (Hedström et al.
1996b). In brief, the test is carried out by
dipping the tip of the test strip into
urine. Trypsinogen-2 in the sample is
bound to monoclonal antibody-labelled
blue latex particles, which migrate across
a nitrocellulose membrane with a catch-
ing zone containing an antibody specific
to an epitope on trypsinogen-2. In Study
III, the urine samples were diluted 40-
fold with phosphate-buffered saline (pH
7.4) containing 1 g/l of bovine serum al-
bumin, protease inhibitors, and preserv-
ative to raise the detection limit from 50
µg/l to 2000 µg/l. The test was consid-
ered positive when a blue line was de-
tected within five minutes. A control line
indicated proper functioning of the strip.
The concentration of trypsinogen-2 in
the samples was also measured by a
quantitative immunoenzymometric as-
say (in-house assay; Medix Biochemica,
Kauniainen, Finland; reference range 0.3
to 11 mg/l) (III).
Serum CRP concentrations were de-
termined by an immunoturbidometric
method. The detection limit was 2 µg/l
and the upper reference limit 10 µg/l.
The coefficient of variation was less
than 8.5% (Kylänpää-Bäck et al. 2001a).
Amylase activity in serum was measured
enzymatically using α-Amylase EPS no
1360221 reagents (Boehringer Mann-
heim, Marburg, Germany). The upper
reference limit was 300 IU/l).
3.2.10 The ERCP procedure
After an overnight fast, patients were
premedicated with pethidine i.m. (Peti-
din; Leiras, Finland) and metoclopra-
mide i.m. (Primperan; Sanofi-Sythelabo)
adjusted for age and tolerance. Prophy-
lactic antibiotics were administered on a
routine basis, with ciprofloxacin 200 mg
i.v. (Ciproxin; Bayer, Leverkusen, Ger-
many) one hour before the investigation.
Senior endoscopists either performed or
supervised the ERCP procedures, which
were carried out with side-viewing Ol-
ympus JF 140 or TJF 140 duodeno-
scopes. Patients received propofol i.v.
(Poropofol “Abbott,” Abbott Laborato-
ries) for sedation and duodenal peristal-
sis was inhibited by boluses of glucagon
i.v. (GlucaGen Novo Nordisk; Denmark)
during the procedure. Omnipaque (Io-
hexol) 140 mg/ml and 240 mg/ml (Ny-
comed, Imaging AS, Oslo, Norway) were
used as a contrast medium. Different
types of commercially available ERCP
cannules were used for the selective can-
nulation of the biliary or pancreatic duct
or both, which was attempted in all pa-
tients; a precut papillotomy was carried
out if necessary. When indicated, proce-
dures such as endoscopic sphincteroto-
my, stone extraction, and stent place-
ment were performed.
3.2.11 Statistics
The results are expressed as mean and
standard deviation (SD) or median and
interquartile range (IQR) unless other-
wise stated (I–V). In Study I, the mean
urinary TAP values were graded between
mild and severe AP using logarithmic
transformation and a one-sided two-
sample t-test. Comparison of continuous
data was performed with the Mann-
Whitney U test (II–V). A p value < 0.05
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was considered statistically significant
(I–V). The validity of the methods
studied for severity grading was evalu-
ated using a receiver-operating charac-
teristics (ROC) curve analysis (Metz et
al. 1998). The area under the curve
(AUC) of the ROC plot describes the ac-
curacy of the test; 1 indicates complete
accuracy and 0.5, no discriminatory
power (I, II, IV). Agreement between
quantitative trypsinogen-2 concentra-
tions and the test strip was evaluated
with the kappa statistic (κ<0.20 indicates
poor agreement, 0.61 to 0.80 good
agreement and κ>0.81 very good agree-
ment) (Landis and Koch 1977) (III). In
Study III, the accuracy of the different
markers were compared using McNe-
mar’s test, and by logistic regression
analysis. The ability of the tests used to
differentiate between study groups was
made by calculating the sensitivity, spe-
cificity, PPV, NPV, and the PLR and neg-
ative likelihood ratio (NLR) (I, II, III).
3.3 Results
3.3.1 The prognostic value of
urinary TAP in patients with acute
pancreatitis within 24 hours of
symptom onset (I)
The study population consisted of 190
patients with AP (I, Table 2) recruited
equally from the three participating cen-
tres (Helsinki, Glasgow and Southamp-
ton). On admission, ROC curve analysis
showed that urinary TAP performed as
well as did CRP or the APACHE II score
in predicting the severity of AP (I, Fig. 2
and 3). The AUC values were for TAP
and CRP, 0.68 and 0.64 (p=NS), and for
TAP and APACHE II, 0.7 and 0.71
(p=NS), respectively. The ROC curve for
the maximum urinary TAP value within
24 hours of hospitalization showed a
very similar patter, to the highest
APACHE II score within the first 24
hours of hospitalization (AUC 0.81 and
0.76; p=NS, respectively) (I, Fig. 4). Uri-
nary TAP appeared to perform better
than did CRP 24 hours after hospitaliza-
tion (AUC 0.81 and 0.66; p=0.046). The
cut-offs and sensitivity, specificity, NPV,
PPV, PLR, and NLR are shown in Table
2. The combination of urinary TAP (cut-
off 25 nmol/l) with CRP (cut-off 100 mg/
l) raised the PLR to 7 and NLR to 0.68
when both exceeded their cut-offs. A
more rigorous definition of severity was
used than that suggested in the Atlanta
document (Bradley 1993). As a result of
the new definition of severity, 24 patients
were categorized as mild who would oth-
erwise have been defined as severe by the
original criteria; none of these patients
died.
3.3.2 Comparison of urinary
trypsinogen-2 with urinary TAP in
the severity assessment of acute
pancreatitis (II).
In this study, 98 (77%) of the 127 pa-
tients with AP exhibited mild disease,
and 29 (23%), severe disease. In patients
with alcohol-induced acute pancreatitis,
the median concentration of urinary
trypsinogen-2 was higher (2240 µg/l,
IQR 102–14390 µg/l) than in those with
gallstone-related disease (115 µg/l, IQR
15–1190 µg/l; P<0.0001), or AP of other
causes (253 µg/l, IQR 22–656 µg/l;
P<0.0001), respectively. That this trend
was also observed for urinary TAP con-
centrations with 14 mg/l (IQR 4–43 µg/l)
for alcohol-induced disease, 6 µg/l (IQR
2–24 µg/l; P=0.006) for gallstone-related
disease, and 5 µg/l (IQR 2–15 µg/l;
P<0.0001) for AP of other causes is in-
teresting. Also, on admission, the sen-
sitivity and specificity of urinary
trypsinogen-2 (cut-off 3000 mg/l) in
predicting severe pancreatitis were 72%
and 81%, respectively, while the corre-
sponding values for urinary TAP (cut-off
35 nmol/l) and serum CRP (cut-off 150
mg/l) were 64% and 82%, and 29% and
32
93%, respectively (II, Table 2). At 24
hours the values were 82% and 78% for
trypsinogen-2, 52% and 92% for TAP,
and 84% and 72% for CRP, respectively
(II, Table 2). The PLR for urinary
trypsinogen-2 was 3.7 on admission and
at 24 hours. The corresponding values
for urinary TAP were 3.6 and 6.8, and for
serum CRP 4.3 and 3.0, respectively (II,
Table 2). In ROC analysis, the AUC-val-
ues for trypsinogen-2 were 0.83 and 0.90
on admission and at 24 hours, for TAP
0.80 and 0.83, and for CRP, 0.64 and
0.86, respectively. The median concen-
trations and time course profiles of uri-
nary trypsinogen-2, urinary TAP, and se-
rum CRP are shown in Fig. 2.
3.3.3 Severity assessment of acute
pancreatitis by novel urinary
trypsinogen-2 test strip (III)
Of the 150 patients, 108 (72%) exhibited
a mild disease and 42 (28%), a severe
disease. On admission, the sensitivity
and specificity of the urinary trypsino-
gen-2 dipstick (cut-off 2000 µg/l) in pre-
dicting severe AP were 62% and 87%, re-
spectively, whereas they were 62% and
77% for the quantitative trypsinogen-2
assay (cut-off 2000 µg/l). On admission,
the sensitivity and specificity of serum
CRP, with the predetermined cut-off of
150 µg/L, were 38% and 90%, respective-
ly (III, Table 1). At 24 hours after hospi-
Table 2. Predictive values and positive and negative likelihood ratios for maximal urinary TAP, CRP, and
APACHE II within 24 hours of hospitalization, Glasgow and Ranson scores at 48 hours, the effect of the
combination of urinary TAP and CRP when either cut-off is exceeded or when both cut-offs are ex-
ceeded within 24 hours, and trypsinogen-2 dipstick and the combination of trypsinogen-2 dipstick and
CRP when either cut-off is exceeded at 24 hours of hospitalization.
Scoring System Cut-off Sensitivity Specificity PPV NPV PLR NLR
(%) (%) (%) (%)
Urinary TAP 25 nmol/l 62 73 28 92 2.3 0.52
Urinary TAP 35 nmol/l 46 80 28 90 2.3 0.68
Serum CRP 150 mg/l 27 86 24 87 1.9 0.85
APACHE II 8 88 48 21 96 1.7 0.25
Glagow 3 69 85 43 95 4.6 0.36
Ranson 3 65 74 28 93 2.5 0.47
Serum CRP 100 mg/l or
Urinary TAP 25 nmol/l 75 55 22 93 1.7 0.45
Serum CRP 100 mg/l and
Urinary TAP 25 nmol/l 35 95 53 89 7 0.68
Trypsinogen-2 dipstick, 2000 µg/L 62 85 62 96 4.2 0.45
Serum CRP >150 mg/L or
Trypsinogen-2 dipstick-positive 93 65 51 96 2.6 0.11
PPV = positive predictive value; NPV = negative predictive value, CRP = C-reactive protein, TAP =
trypsinogen activation peptide, PLR = positive likelihood ratio, NLR = negative likelihood ratio.
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talization, the sensitivity and specificity
for the rapid dipstick were 62% and 85%
(Table 2), whereas they were 71% and
78% for the quantitative assay, respec-
tively. For serum CRP, the corresponding
values were 83% and 70% (III, Table 1).
The PLR of the urinary trypsinogen-2
dipstick test was on admission, 4.8, and
at 24 hours 4.2, while the corresponding
values for CRP were 3.7 and 2.7, respec-
tively (III, Table 1). Comparisons of the
results for the dipstick test with the
quantitative assay indicate fairly good
agreement κ=0.68 (III, Fig. 1). The prog-
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Fig. 2. (A) Median (25th
and 75th percentile) val-
ues of urinary trypsino-
gen-2 concentrations on
admission, 12, 24, 36,
48, 72, 96 and 120 hours
after admission in pa-
tients with mild and se-
vere acute pancreatitis.
(B) The values of uri-
nary TAP concentra-
tions at the same time
intervals. (C) Serum
CRP concentrations at
the same time intervals.
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nostic accuracy of the dipstick test was
compared with that of CRP at a cut-off
providing the same sensitivity (62%) for
both tests. On admission, the dipstick
test showed better specificity than did
CRP (p=0.00036, McNemar’s test). At 24
hours, however, the difference reached
no statistical significance (the sensitivity
of each test was 61%; p=0.291). When
either CRP was >150 µg/L or the
trypsinogen-2 dipstick was positive at 24
hours, 93 of the patients developing se-
vere disease were identified (Table 2).
3.3.4 Sequential changes in concen-
trations of trypsinogen-1, trypsino-
gen-2, complexes of trypsin-1 and
trypsin-2 with α
1
-antitrypsin, TAP
and PSTI in serum and urine of pa-
tients with acute pancreatitis (IV).
The study-population consisted of 64
consecutive patients with AP of which 19
(30%) had severe disease and 45 (70%),
mild disease; 32 patients with acute ab-
domen of nonpancreatic origin served as
controls (IV, Table I).
In serum, the concentrations of
trypsinogen-1 and -2 showed similar pat-
terns (IV, Fig. 1A and 2A), but the excre-
tion of trypsinogen-1 into urine was
much lower (IV, Fig. 1B) than that of
trypsinogen-2, which occurred at very
high concentrations, especially in severe
AP, and correlated strongly with disease
severity (IV, Fig. 2B). The concentration
of the T1-AAT complex in serum in-
creased gradually and differed only mod-
erately between patients with mild and se-
vere disease (IV, Fig. 1C). On the contrary,
T2-AAT concentrations were significantly
higher in severe than in mild disease (IV,
Fig. 2C). In AP, the concentrations of
PSTI in urine increased much more
sharply than did those in serum. Urinary
PSTI showed strong correlation with dis-
ease severity (IV, Fig. 3B). The concentra-
tions of plasma TAP decreased rapidly
after admission, reaching undetectable
levels within 48 hours. The temporal ki-
netics of urinary TAP showed a similar
pattern. During the very early phase, TAP
correlated well with disease severity in
plasma and urine, but no difference could
be observed between controls and pa-
tients with mild AP (IV, Fig. 4A and B).
On admission, urinary trypsinogen-
2 showed the greatest accuracy in assess-
ing disease severity with an AUC value of
0.875, followed by plasma TAP with an
AUC value of 0.823, and urinary PSTI
with an AUC value of 0.811, respectively.
At 24 hours after admission, the best
prognostic accuracy was obtained with
urinary PSTI, urinary trypsinogen-2,
and urinary trypsinogen-1, the AUC val-
ues of which were 0.945, 0.925, and
0.904, respectively (IV, Table III).
3.3.5 Early sequential changes in
serum concentrations of trypsino-
gen-1 and -2, and complexes of
trypsin-2 with α
1
-antitrypsin and
PSTI in patients with post-ERCP
pancreatitis (V)
AP developed after 50 of the 897 ERCP
procedures (5.6%). In all cases the ERCP
procedure was therapeutic. According to
the Atlanta classification, all but two cases
were mild (Bradley 1993). Sixty-one ran-
domly-selected patients without post-
ERCP pancreatitis served as controls. All
but one of the ERCP procedures in the
control group was therapeutic.
There was a 10-fold increase from
baseline in serum trypsinogen-1 already
at two hours after ERCP in patients de-
veloping AP, and the median concentra-
tion was 15-fold that of controls (Fig.
3A). In patients with AP, the concentra-
tion gradually decreased over the next 48
hours, whereas the control group saw no
significantly change. Interestingly, the
baseline concentrations of trypsinogen-1
before ERCP were markedly higher
(p=0.026) in patients developing AP
than in those who were not (Fig. 3A).
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Fig. 3. (A) Median (25th and 75th percentile) values of serum trypsinogen-1 concentrations
prior to ERCP and 2, 6, 24, 48, 72, 96 and 120 hours after ERCP in patients developing
post-ERCP pancreatitis, and in controls. (B) The values of serum trypsinogen-2 concen-
trations at the same time intervals. (C) Serum trypsin-2-α
1
-antitrypsin (T2-AAT) concen-
trations at the same time intervals. *P<0.05, **<0.001 patients with post-ERCP pancreati-
tis versus controls.
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The serum trypsinogen-2 concentra-
tion in patients developing AP increased
10-fold from baseline already after 2
hours (Fig. 3B). The concentrations de-
creased more slowly than did those of
trypsinogen-1. In the controls, the con-
centrations remained fairly constant.
The concentrations of T2-AAT in
patients with post-ERCP pancreatitis dif-
fered from those of trypsinogens by in-
creasing more slowly, peaking first from
24 to 48 hours after ERCP. An 8-fold in-
Fig. 4. (A) Median (25th and 75th percentile) values of serum PSTI prior to ERCP and 2, 6,
24, 48, 72, 96 and 120 hours after ERCP in patients developing post-ERCP pancreatitis,
and in controls. (B) The values of serum CRP concentrations at the same time intervals.
*P<0.05, **<0.001 patients with post-ERCP pancreatitis versus controls.
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crease was observed at 48 hours in those
patients developing AP (Fig. 3C).
Serum PSTI concentrations in-
creased rapidly during the first two
hours in patients developing AP, and
during the next 48 hours they were
about 2-fold those of controls, in which
the concentrations remained fairly con-
stant. After the rapid initial rise in pa-
tients with AP, PSTI concentrations
dropped slightly during the first 48
hours, and rose again later (Fig. 4A).
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No marked increase in serum CRP
was observed during the first six hours af-
ter ERCP in patients developing post-
ERCP pancreatits. However, at 24 hours
the median concentration was 2-fold that
of controls, and rose steadily for up to 72
hours in those developing AP (Fig. 4B),
whereas the concentrations remained
constant in the controls. No marked dif-
ference was observed in the concentra-
tions of the different markers between the
two severe cases and the less severe cases.
3.4 Discussion
3.4.1 The prognostic value of uri-
nary TAP in the early phase of acute
pancreatitis (I, II).
The pivotal role of trypsinogen activa-
tion in the pathogenesis of AP makes
trypsin-based laboratory assays poten-
tially useful in severity assessment.
In the multicenter study (I) on the
prognostic value of urinary TAP in the se-
verity assessment of AP, urinary TAP con-
firmed its usefulness as a predictor of se-
verity in the very early phase of the
disease. There was a clear separation be-
tween the mean urinary TAP values ob-
served in patients with mild and severe
disease. The sensitivity and specificity
(cut-off 25 nmol/l) within 24 hours of
hospitalization were 62% and 73%, re-
spectively (I, Table 5). These figures were
similar to those obtained in Study II (cut-
off 35 nmol/l), where the sensitivity and
specificity were 64% and 82% on admis-
sion, respectively (II, Table 2). These fig-
ures are comparable to previous studies
on urinary TAP (Neoptolemos et al.
2000). In both of these studies the interval
between the onset of symptoms and entry
into the study was relatively short even
though the urinary TAP levels correlated
with disease severity. This is consistent
with the hypothesis that trypsinogen acti-
vation is an early key event in the patho-
genesis of AP (Steer 1998).
The ROC curve indicates a lower
cut-off (25 nmo/l) value for urinary TAP
concentration than previously deter-
mined (35 nmol/l) (Neoptolemos et al.
2000). One argue, however, that the opti-
mal cut-off value obtained in the present
study (I) was appropriate, because the
predetermined value (also used in Study
II) was derived from earlier work with
patients having a longer duration of
symptoms before sampling. Likewise, the
optimal cut-off value for CRP was lower
(100 mg/l) than the value now generally
accepted for samples obtained later in
the course of the disease (Dervenis et al.
1999).
As expected, the combination of tests
affected the predictive values obtained.
The combination of CRP and TAP in-
creased specificity, so that when both
cut-offs are exceeded, over half of the pa-
tients will have severe disease. However,
defining severity by choosing either TAP
or CRP above the cut-off value, increases
sensitivity, and when both tests are nega-
tive, only 7% of patients will develop
complications. Clearly, one must recog-
nize that none of these tests or combina-
tions can be considered ideal. Although
TAP offers a slight improvement in pre-
dictive value, it seems likely that a com-
bination of tests is needed if TAP is used.
That urinary TAP concentrations were
higher in patients with alcohol-induced
AP than in those with gallstone-related
disease in interesting (II). In Study I, no
difference was observed between the eti-
ologies, and to our knowledge, no differ-
ences have previously been reported in
urinary TAP values with regard to etiolo-
gy (Gudgeon et al. 1990; Tenner et al.
1997; Neoptolemos et al. 2000). The dif-
ference found in Study II may partly be
explained by the relatively small propor-
tion of severe cases of etiologies other
than alcohol.
It seems justified to conclude, based
on the results, that early prediction of se-
verity is difficult. Estimation of TAP con-
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centrations can, however, contribute to
the prediction of severe disease, and the
combination of TAP with CRP improves
predictive accuracy. Moreover, the use of
the more rigorous definition of severity
(I) also seems justified, given that a rapid
resolution of organ failure does not in-
crease the risk of complications.
3.4.2 Evaluation of the accuracy of
urinary trypsinogen-2, urinary TAP,
serum CRP, and APACHE II in their
ability to differentiate between
patients with severe and mild acute
pancreatitis (II, III).
Previous studies have shown that the
pattern of urinary trypsinogen-2 and
urinary TAP are very similar (Kemp-
painen et al. 2000; Neoptolemos et al.
2000).
The results in these present studies
(II and III) show that urinary trypsino-
gen-2 is a better marker than serum CRP
and APACE II, and as good as or even
better than urinary TAP (II) in the early
assessment of disease severity in AP. Fur-
thermore, trypsinogen-2 has the advan-
tage over TAP that it can be determined
in urine with a rapid dipstick test. The
test, with a detection limit of 50 mg/l,
has proven to be a sensitive marker for
the diagnosis of acute pancreatitis
(Kemppainen et al. 1997b; Kylänpää-
Bäck et al. 2000). The detection limit,
however, can be raised by a dilution set
(III). This was used to predict severity in
AP in Study III, where diluted urine
samples were tested with the rapid uri-
nary trypsinogen-2 dipstick test (Actim
Pancreatitis, Medix Biochemica). The re-
sult of the test is available within five
minutes, whereas TAP requires a labori-
ous ELISA method, which takes several
hours and requires skilled laboratory
personnel. The dipstick test requires no
laboratory equipment and can be per-
formed by nursing personnel. In this re-
spect, the rapid trypsinogen-2 measure-
ment shows a clear advantage over uri-
nary TAP.
Although the trypsinogen-2 dipstick
test was clearly more accurate than CRP
at presentation, about one third of cases
developing severe AP were missed with
the cut-off used. However, earlier studies
have shown that, when used with undilut-
ed urine and using a cut-off of 50 mg/l,
the dipstick test identifies all cases of se-
vere AP. Thus, by lowering the cut-off, it is
possible to increase sensitivity, which is
naturally associated with loss of specifici-
ty. A positive result with either the dip-
stick or a CRP >150 mg/l within 24 hours
after admission detected 93% of cases
with severe AP, giving an NPV of 96%.
This result is similar to that achieved with
the combination with CRP and urinary
TAP in Study I, where the figures were
75% and 93%, respectively.
Multi-factorial scoring systems are of-
ten used in clinical trials to assess the se-
verity of AP. Although APACHE II has an
advantage over other clinico-biochemical
scoring systems in that it can be used im-
mediately on admission and can be meas-
ured serially, its complexity limits its use
in clinical practice (Toh et al. 2000). In
these present studies, the APACHE II
score with a cut-off of eight did not reach
the accuracy of either the quantitative
urinary trypsinogen-2 measurement or
the dipstick tests in predicting severe AP
within 24 hours after admission (II, III).
At 48 hours, the prognostic accuracy of
trypsinogen-2 and the multi-factorial
scoring systems were, however, similar as
evaluated by ROC analysis, the AUC val-
ues being 0.87 for urinary trypsinogen-2
and 0.88 for APACHE II, respectively (II).
Evaluation at 48 hours after admission is,
however, too late for early therapeutic de-
cision-making.
In conclusion, these results suggest
that urinary trypsinogen-2 is at least as
good as urinary TAP, and that the test
strip in combination with other tests is
useful in the severity assessment of AP.
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3.4.3 Sequential changes in pancre-
atic markers in acute pancreatitis
(IV–V).
The recent discovery of mutations in the
trypsinogen-1 gene, presumably prevent-
ing the inactivation of trypsin-1, has led
to the notion that trypsin-1 may be a key
enzyme in the pathogenesis of AP, and
that it is more important than trypsin-2
(Whitcomb 1999b). Under normal con-
ditions the serum concentrations of
trypsinogen-1 have been reported to be
higher than those of trypsinogen-2
(Kimland et al. 1989), but only small
amounts are recovered in urine (Borg-
ström and Ohlsson 1978). In keeping
with earlier findings, however, we found
that during AP, the ratio is reversed: the
concentrations of trypsinogen-2 are
much higher than those of trypsinogen-
1 (Itkonen et al. 1990). Furthermore, the
concentrations of trypsinogen-2 corre-
lated strongly with disease severity, thus
confirming earlier findings (Itkonen et
al. 1990; Hedström et al. 1996d; Sainio et
al. 1996). In patients with AP, the serum
concentrations of trypsinogen-2 were on
average 10-fold those of trypsinogen-1,
and in urine the differences were even
more striking (i.e. almost 14000-fold)
(IV, Table V). Furthermore, the serum
concentrations of trypsinogen-2 re-
mained elevated longer than did those of
trypsinogen-1 (V). This explains why
trypsinogen-2 is a more useful marker
both for the diagnosis and severity as-
sessment of AP in the typical clinical set-
ting, where the time span between the
induction of AP and arrival at the emer-
gency department may be several days.
It is probable that a drastic increase
in the urine concentrations of trypsino-
gen-2 is at least partially due to a dis-
turbed reabsorption associated with a
grossly increased excretion of protein
fragments and peptides resulting from
extensive tissue damage (Hedström et al.
1996d). Thus the urine levels would re-
flect not only the release of trypsinogen-
2 from the pancreas, but also the degree
of tissue damage in AP. This would ex-
plain the strong correlation with the se-
verity of the disease.
Interestingly, prior to ERCP, the me-
dian concentration of serum trypsino-
gen-1 was markedly higher in patients
developing post-ERCP pancreatitis than
in the controls. It is notable that
trypsinogen-2 levels were not signifi-
cantly elevated. Therefore, it is tempting
to speculate, that a high trypsinogen-1
concentration may be a risk factor in the
development of post-ERCP pancreatitis
and AP in general. These findings also
agree with the theory that trypsinogen-1
autoactivates more easily than does
trypsinogen-2 (Colomb et al. 1979).
These findings support the hypothesis
that trypsinogen-1 may be more impor-
tant than trypsinogen-2 in the initiation
phase of AP, but do not deny a role for
trypsinogen-2, especially in the later
phase of the disease (Kukor et al. 2003).
The reasons for the low trypsinogen-
1 concentrations in urine remain un-
known, but the low concentrations could
result from both more efficient reab-
sorption or more rapid degradation.
Studies in dogs have shown that there is
a variable tubular uptake of trypsinogen-
2 and a rather complete tubular uptake
of trypsinogen-1 (Ohlsson 1971). On ad-
mission, the serum concentrations of the
T1-AAT complex showed no difference
between mild and severe AP or between
AP and controls (IV, Fig. 1). Unfortu-
nately, T1-AAT could not be measured in
Study V in the initial phase of the dis-
ease. In contrast, the serum concentra-
tions of T2-AAT differed between all
three groups studied already on admis-
sion, and they correlated with disease se-
verity (IV, Fig 2). The T2-AAT concen-
trations rose more sharply than did those
of T1-AAT in patients with AP (V), re-
flecting the high trypsinogen-2 concen-
trations.
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PSTI is belived to act as the first de-
fense against premature trypsinogen ac-
tivation in the pancreas by inhibiting
prematurely-activated trypsin within the
pancreas. Serum PSTI has been shown to
be a marker of the severity of AP (Pezzil-
li et al. 1994), and elevated urinary PSTI
concentrations have been observed in
patients with AP (Eddeland and Ohlsson
1978a; Kitahara et al. 1980). Urinary
PSTI concentrations correlated strongly
with severe AP in Study IV, but the levels
were similar in controls and in patients
with mild AP. In AP, the initially-released
PSTI is probably of pancreatic origin,
however, the late increase may derive
from other sources, since significant
amounts of PSTI are produced outside
the pancreas (Stenman 2002), and it also
acts as an acute phase reactant (Ogawa
1988). Our findings suggest that when
the inhibitory capacity of the “primary”
intrapancreatic trypsin inhibitor PSTI is
exceeded after about 24 hours, the com-
plex formation with inhibitors in plasma,
such as AAT, becomes evident. These
mechanisms could explain why T2-AAT
in serum increases much later than do
trypsinogen-1, -2, and PSTI.
Somewhat surprisingly, we found no
correlation between plasma TAP and T1-
AAT or T2-ATT concentrations (IV).
This could partly result from the differ-
ent half-lives of the markers in circula-
tion (8 minutes for TAP, and 45 minutes
for ATT) (Ohlsson 1971; Simpson et al.
1995), as well as from the sequential
trypsin inhibition cascade, in which
trypsin released from the PSTI-trypsin
complex is recovered bound to α
2
-mac-
roglobulin, and the rest shows equal par-
tition between PSTI and AAT (Eddeland
and Ohlsson 1978b).
In conclusion, our findings demon-
strate an equally steep increase of
trypsinogen-1 and -2 in the very early
phase of AP. Trypsinogen-2 remained ele-
vated longer than did trypsinogen-1, and
later, more pronounced changes occurred
in trypsinogen-2 and its complex with
AAT than in those of trypsinogen-1. This
suggests that trypsinogen-2 might play a
more important role in the pathogenesis
of AP than previously thought, especially
in the later phase of the disease. The ele-
vation of the T2-AAT complex in circula-
tion might reflect the exhaustion of the
intrapancreatic PSTI-based defense
mechanisms against trypsin activation.
Furthermore, urinary PSTI warrants fur-
ther investigation as a marker of disease
severity. An essential drawback is that the
markers used, except for trypsinogen-2
dipstick, are not applicable in the clinical
routine, limiting their utility.
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3.5 Conclusions
On the basis of this present study, these
new results justify the following conclu-
sions.
1.  The measurement of urinary TAP
concentrations is useful in the predic-
tion of a severe outcome in patients
who arrive at the hospital within the
first 24 hours of onset of symptoms.
Urinary trypsinogen-2 measurement
is at least as accurate as urinary TAP
in predicting severe AP in the early
phase of the disease, and clearly supe-
rior to serum CRP and the APACHE
II score.
2. Patients with organ failure that re-
solves within 48h are unlikely to de-
velop complications later in the
course of their illness; these patients
should not be classified as severe AP.
3. The urinary trypsinogen-2 test strip
with a detection limit of 2000 µg/L is
a novel way of determining the sever-
ity of AP. Results from the rapid uri-
nary test strip are obtained in five
minutes and require no laboratory
equipment. A positive result in com-
bination with a serum CRP >150 mg/l
rapidly identifies patients requiring
further evaluation and therapeutic
measures in the early phase of the
disease.
4. In AP, more pronounced changes
were observed in trypsinogen-2 and
its complex with AAT than in
trypsinogen-1. This suggests that
trypsinogen-2 might play a more sig-
nificant role in the pathogenesis of
AP than previoulsy thought. Urinary
PSTI concentrations rise more sharp-
ly than do those in serum, and corre-
late more strongly with the severity
of AP.
5. In the very early phase of AP, the se-
rum concentrations of trypsinogen-1
and -2 in patients with ERCP-in-
duced AP show an equally steep in-
crease, but trypsinogen-2 remains el-
evated over a longer period. Serum
PSTI also increases rapidly within
hours of disease onset, while T2-AAT
peaks only 24 to 48 hours later. The
late elevation of T2-AAT in circula-
tion may reflect exhaustion of the in-
trapancreatic PSTI-based defense
mechanism against trypsin activa-
tion.
Timely recognition of those patients
who will develop complications of AP is
still a challenge. At present, no single bi-
ochemical marker suits this purpose ide-
ally. The best results will be achieved by
using a combination of different tests.
Future studies on various combinations
are needed to show which combination
will be most useful in predicting the se-
verity of AP.
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